Our team is heading to ACTRIMS 2/29-3/2 and we look forward to connecting with you! More

Our Science

Powerful innovation to transform MS

We're committed to rigorous and ongoing evaluation.

Browse our latest publications below.

Multivariate protein biomarker models more accurately predict multiple sclerosis MRI disease activity compared to serum levels of neurofilament light chain alone

High throughput lesion evaluation and quality control for incorporating quantitative imaging metrics into clinical practice

BrainGraph: A Novel Visualization of MRI Data as a 3D Graph to Reveal Temporal Features of Disease Progression In Patients with Multiple Sclerosis

Improving Patient Outcomes through a Comprehensive Care Management Platform Measuring Outcomes and Value: an Integrated, Novel solution for Generating insights in MS (MOVING MS)

Clinical Validation of a Multivariate Proteomic Serum Based Assay for Disease Activity Assessments in Multiple Sclerosis

Analytical Validation of a Multivariate Proteomic Serum Based Assay for Disease Activity Assessments in Multiple Sclerosis

Changes in the Detection of Clinically Relevant White Matter Lesions in MS Using FDA-Cleared Automated Software

Development of a Custom Multivariate Proteomic Serum Based Assay for Association with Radiographic and Clinical Endpoints in MS

Integrated Analysis of Novel MRI and Blood Serum Biomarkers for the Estimation and Prediction of MS Disease Activity and Progression

Proteomic Serum Biomarker Signatures Associated with Patient Reported Outcomes in Multiple Sclerosis

1 6 7 8

Multivariate protein biomarker models more accurately predict multiple sclerosis MRI disease activity compared to serum levels of neurofilament light chain alone

High throughput lesion evaluation and quality control for incorporating quantitative imaging metrics into clinical practice

BrainGraph: A Novel Visualization of MRI Data as a 3D Graph to Reveal Temporal Features of Disease Progression In Patients with Multiple Sclerosis

Improving Patient Outcomes through a Comprehensive Care Management Platform Measuring Outcomes and Value: an Integrated, Novel solution for Generating insights in MS (MOVING MS)

Clinical Validation of a Multivariate Proteomic Serum Based Assay for Disease Activity Assessments in Multiple Sclerosis

Analytical Validation of a Multivariate Proteomic Serum Based Assay for Disease Activity Assessments in Multiple Sclerosis

Changes in the Detection of Clinically Relevant White Matter Lesions in MS Using FDA-Cleared Automated Software

Development of a Custom Multivariate Proteomic Serum Based Assay for Association with Radiographic and Clinical Endpoints in MS

Integrated Analysis of Novel MRI and Blood Serum Biomarkers for the Estimation and Prediction of MS Disease Activity and Progression

Proteomic Serum Biomarker Signatures Associated with Patient Reported Outcomes in Multiple Sclerosis